ATC Group: A02BX02 Sucralfate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BX02 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A02 Drugs for acid related disorders
3 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
5 A02BX02 Sucralfate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 4 g

Active ingredients in A02BX02

Active Ingredient Description
Sucralfate

Sucralfate forms an ulcer adherent complex with the proteinaceous exudate of the ulcer site. This property enables sucralfate to form a protective barrier over the ulcer lesion giving sustained protection against the penetration and action of gastric acid, pepsin and bile.

Related product monographs

Title Information Source Document Type  
CARAFATE Tablet FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Mexico (MX)

New Zealand (NZ)

Poland (PL)

Romania (RO)

South Africa (ZA)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.